Brief: Jacobio Pharmaceuticals Says KRAS G12C Inhibitor Jab-21822 Granted Breakthrough Therapy Designations
15/12/2022 22:12
Dec 16 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* KRAS G12C INHIBITOR JAB-21822 WAS GRANTED BREAKTHROUGH
THERAPY
DESIGNATIONS BY CENTER FOR DRUG EVALUATION
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan